Article

Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; A case report

2022-05-13

Abstract excerpt

Dacomitinib is an irreversible, oral small-molecule inhibitor of not only EGFR but also the entire ErbB family. Both dacomitinib and afatinib are classified as second-generation EGFR-TKIs (tyrosine kinase inhibitors). Afatinib was approved in 2013, prior to dacomitinib, which was approved later in 2018. In the meantime, osimertinib, a third-generation EGFR-TKI, was approved in 2015. Consequently, the position of d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 83af0cc7-b384-5a20-a32b-75c316824489
DOI: 10.21203/rs.3.rs-1613880/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; A case reportDOI 10.21203/rs.3.rs-1613880/v1Read

Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.Semantic proximity Read

Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.Semantic proximity Read

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.Semantic proximity Read

A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case reportSemantic proximity Read

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.Semantic proximity Read

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.Semantic proximity Read

Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.Semantic proximity Read

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read

Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.Semantic proximity Read

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.Semantic proximity Read

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Semantic proximity Read

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?Semantic proximity Read